688578.SS in “China Becomes Pharma's Global R&D Engine”
Shanghai Allist Pharmaceuticals Co., Ltd.
Allist's EGFR inhibitor furmonertinib has generated international development exposure through ArriVent, illustrating how Chinese clinical assets can be advanced globally by Western partners.
688578.SS impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 688578.SS’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 688578.SS impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 241 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — Allist's EGFR inhibitor furmonertinib has generated international development exposure through ArriVent, illustrating how Chinese clinical assets can be advanced globally by Western partners.
Read the full China Becomes Pharma's Global R&D Engine story